Safety profile of proprotein convertase subtilisin/kexin type 9 inhibitors alirocumab and evolocumab: an updated meta-analysis and meta-regression-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Safety profile of proprotein convertase subtilisin/kexin type 9 inhibitors alirocumab and evolocumab: an updated meta-analysis and meta-regression

Published:2024-06-11 Issue:7 Volume:40 Page:1103-1121
ISSN:0300-7995
Container-title:Current Medical Research and Opinion
language:en
Short-container-title:Current Medical Research and Opinion

Author:

Rivera Frederick Berro¹^ORCID,Cha Sung Whoy²,Magalong John Vincent³,Bantayan Nathan Ross B.⁴,Cruz Linnaeus Louisse A.⁴,Arias-Aguirre Eloise²,Aguirre Zedrick²^ORCID,Varona Michelle Capahi²,Co Elaiza Marie Fernandez²,Lumbang Grace Nooriza Opay²,Enkhmaa Byambaa⁵

Affiliation:

1. Department of Medicine, Lincoln Medical Center, New York, NY, USA

2. Cebu Institute of Medicine, Cebu City, Philippines

3. College of Medicine, San Beda University, Manila, Philippines

4. University of the Philippines College of Medicine, Manila, Philippines

5. Division of Endocrinology, Diabetes & Metabolism, UC Davis Health, Davis, CA, USA

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/03007995.2024.2363971

Reference60 articles.

1. A Systematic Review of PCSK9 Inhibitors Alirocumab and Evolocumab

2. The PCSK9 revolution: Current status, controversies, and future directions

3. A Comprehensive Review of PCSK9 Inhibitors

4. Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events

5. Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP